INCA033989 showed responses across type 1 and type 2 mutant calreticulin-positive myelofibrosis, with phase 3 studies underway.
Claire Harrison, MD
Advertisement
Claire Harrison, MD, is a professor of hematology at the Guy's and St. Thomas' NHS Foundation Trust in London, England.
Articles by Claire Harrison, MD
INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting disease-modifying potential.
INCA033989 demonstrated spleen reductions, anemia responses, and molecular improvements in patients with mutant calreticulin–positive myelofibrosis.
Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.
Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants
3
Dermatology Practices Absorb Rising Prior Authorization Costs
4
Dry Eye Disease Is More Than "Dry Eyes": Experts Explain the 2 Types
5